Visfatin and cardio-cerebro-vascular disease

Journal of Cardiovascular Pharmacology

Volumn 59, Issue 1, 2012, Pages 1-9

  Wang, Pei ^a   Vanhoutte, Paul M ^b   Miao, Chao Yu ^a,c  

^a SECOND MILITARY MEDICAL UNIVERSITY   (China)

^b UNIVERSITY OF HONG KONG   (Hong Kong)

^c SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

Author keywords

adipokine; atherosclerosis; coronary artery disease; hypertension; stroke; vascular biology

Indexed keywords

NICOTINAMIDE PHOSPHORIBOSYLTRANSFERASE;

ATHEROSCLEROSIS; BLOOD VESSEL TONE; BRAIN ISCHEMIA; CARDIOVASCULAR DISEASE; CEREBROVASCULAR DISEASE; ENDOTHELIUM CELL; HUMAN; HYPERTENSION; ISCHEMIC HEART DISEASE; NONHUMAN; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN STRUCTURE; REVIEW; SMOOTH MUSCLE FIBER; VASCULAR SMOOTH MUSCLE;

ADIPOSE TISSUE; ANIMALS; CARDIOVASCULAR DISEASES; CEREBROVASCULAR DISORDERS; ENDOTHELIUM, VASCULAR; HUMANS; NICOTINAMIDE PHOSPHORIBOSYLTRANSFERASE;

EID: 84855351865     PISSN: 01602446     EISSN: 15334023     Source Type: Journal    
DOI: 10.1097/FJC.0b013e31820eb8f6     Document Type: Review

References (143)

1. Kahn BB, Flier JS. Obesity and insulin resistance. J Clin Invest. 2000;106:473-481. (Pubitemid 30666380)
2. Thompson D, Wolf AM. The medical-care cost burden of obesity. Obes ev. 2001;2:189-197.
3. Wang P, Mariman E, Renes J, et al. The secretory function of adipocytes in the physiology of white adipose tissue. J Cell Physiol. 2008;216:3-13. (Pubitemid 351813090)
4. Poulos SP, Hausman DB, Hausman GJ. The development and endocrine functions of adipose tissue. Mol Cell Endocrinol. 2010;323:20-34.
5. Nedergaard J, Cannon B. The changed metabolic world with human brown adipose tissue: therapeutic visions. Cell Metab. 2010;11:268-272.
6. Zhang Y, Proenca R, Maffei M, et al. Positional cloning of the mouse obese gene and its human homologue. Nature. 1994;372:425-432. (Pubitemid 24365442)
7. Antoniades C, Antonopoulos AS, Tousoulis D, et al. Adiponectin: from obesity to cardiovascular disease. Obes Rev. 2009;10:269-279.
8. Gomez-Ambrosi J, Fruhbeck G. Evidence for the involvement of resistin in inflammation and cardiovascular disease. Curr Diabetes Rev. 2005;1:227-234.
9. Wada J. Vaspin: a novel serpin with insulin-sensitizing effects. Expert Opin Invest Drugs. 2008;17:327-333. (Pubitemid 351578185)
10. Fukuhara A, Matsuda M, Nishizawa M, et al. Visfatin: a protein secreted by visceral fat that mimics the effects of insulin. Science. 2005;307:426-430. (Pubitemid 40139988)
11. Samal B, Sun Y, Stearns G, et al. Cloning and characterization of the cDNA encoding a novel human pre-B-cell colony-enhancing factor. Mol Cell Biol. 1994;14:1431-1437.
12. Rongvaux A, Shea RJ, Mulks MH, et al. Pre-B-cell colony-enhancing factor, whose expression is up-regulated in activated lymphocytes, is a nicotinamide phosphoribosyltransferase, a cytosolic enzyme involved in NAD biosynthesis. Eur J Immunol. 2002;32:3225-3234. (Pubitemid 35414880)
13. Revollo JR, Korner A, Mills KF, et al. Nampt/PBEF/Visfatin regulates insulin secretion in beta cells as a systemic NAD biosynthetic enzyme. Cell Metab. 2007;6:363-375. (Pubitemid 350011996)
14. Hallschmid M, Randeva H, Tan BK, et al. Relationship between cerebrospinal fluid visfatin (PBEF/Nampt) levels and adiposity in humans. Diabetes. 2009;58:637-640.
15. Laudes M, Oberhauser F, Schulte DM, et al. Visfatin/PBEF/Nampt and resistin expressions in circulating blood monocytes are differentially related to obesity and Type 2 diabetes in humans. Horm Metab Res. 2010;42:268-273.
16. Sethi JK, Vidal-Puig A. Visfatin: the missing link between intra-abdominal obesity and diabetes? Trends Mol Med. 2005;11:344-347. (Pubitemid 41080573)
17. Moschen AR, Kaser A, Enrich B, et al. Visfatin, an adipocytokine with proinflammatory and immunomodulating properties. J Immunol. 2007;178:1748-1758. (Pubitemid 46154646)
18. Rongvaux A, Galli M, Denanglaire S, et al. Nicotinamide phosphoribosyl transferase/pre-B cell colony-enhancing factor/visfatin is required for lymphocyte development and cellular resistance to genotoxic stress. J Immunol. 2008;181:4685-4695.
19. Li H, Liu P, Cepeda J, et al. Augmentation of pulmonary epithelial cell IL-8 expression and permeability by pre-B-cell colony enhancing factor. J Inflamm (Lond). 2008;5:15.
20. Yang H, Yang T, Baur JA, et al. Nutrient-sensitive mitochondrial NAD+ levels dictate cell survival. Cell. 2007;130:1095-1107. (Pubitemid 47410271)
21. Yang H, Lavu S, Sinclair DA. Nampt/PBEF/Visfatin: a regulator of mammalian health and longevity? Exp Gerontol. 2006;41:718-726. (Pubitemid 44223900)
22. Benigni A, Corna D, Zoja C, et al. Disruption of the Ang II type 1 receptor promotes longevity in mice. J Clin Invest. 2009;119:524-530.
23. Sinclair DA. Toward a unified theory of caloric restriction and longevity regulation. Mech Ageing Dev. 2005;126:987-1002. (Pubitemid 41033180)
24. Nakahata Y, Sahar S, Astarita G, et al. Circadian control of the NAD+ salvage pathway by CLOCK-SIRT1. Science. 2009;324:654-657.
25. Ramsey KM, Yoshino J, Brace CS, et al. Circadian clock feedback cycle through NAMPT-mediated NAD+ biosynthesis. Science. 2009;324:651-654.
26. Ognjanovic S, Bao S, Yamamoto SY, et al. Genomic organization of the gene coding for human pre-B-cell colony enhancing factor and expression in human fetal membranes. J Mol Endocrinol. 2001;26:107-117. (Pubitemid 32266186)
27. Tanaka M, Nozaki M, Fukuhara A, et al. Visfatin is released from 3T3-L1 adipocytes via a non-classical pathway. Biochem Biophys Res Commun. 2007;359:194-201. (Pubitemid 46880493)
28. Garten A, Petzold S, Barnikol-Oettler A, et al. Nicotinamide phosphoribosyltransferase (NAMPT/PBEF/visfatin) is constitutively released from human hepatocytes. Biochem Biophys Res Commun. 2010;391:376-381.
29. Kitani T, Okuno S, Fujisawa H. Growth phase-dependent changes in the subcellular localization of pre-B-cell colony-enhancing factor. FEBS Lett. 2003;544:74-78. (Pubitemid 36628039)
30. Muller WE, Perovic S, Wilkesman J, et al. Increased gene expression of a cytokine-related molecule and profilin after activation of Suberites domuncula cells with xenogeneic sponge molecule(s). DNA Cell Biol. 1999;18:885-893. (Pubitemid 30013441)
31. Martin PR, Shea RJ, Mulks MH. Identification of a plasmid-encoded gene from Haemophilus ducreyi which confers NAD independence. J Bacteriol. 2001;183:1168-1174. (Pubitemid 32107712)
32. Fujiki K, Shin DH, Nakao M, et al. Molecular cloning and expression analysis of the putative carp (Cyprinus carpio) pre-B cell enhancing factor. Fish Shellfish Immunol. 2000;10:383-385.
33. Tang H, Cheung WM, Ip FC, et al. Identification and characterization of differentially expressed genes in denervated muscle. Mol Cell Neurosci. 2000;16:127-140. (Pubitemid 30651176)
34. Van Beijnum JR, Moerkerk PT, Gerbers AJ, et al. Target validation for genomics using peptide-specific phage antibodies: a study of five gene products overexpressed in colorectal cancer. Int J Cancer. 2002;101:118-127. (Pubitemid 34970903)
35. Wang T, Zhang X, Bheda P, et al. Structure of Nampt/PBEF/visfatin, a mammalian NAD+ biosynthetic enzyme. Nat Struct Mol Biol. 2006;13:661-662. (Pubitemid 44036478)
36. Kim MK, Lee JH, Kim H, et al. Crystal structure of visfatin/pre-B cell colony-enhancing factor 1/nicotinamide phosphoribosyltransferase, free and in complex with the anti-cancer agent FK-866. J Mol Biol. 2006;362:66-77. (Pubitemid 44262358)
37. Burgos ES, Ho MC, Almo SC, et al. A phosphoenzyme mimic, overlapping catalytic sites and reaction coordinate motion for human NAMPT. Proc Natl Acad Sci U S A. 2009;106:13748-13753.
38. Kang GB, Bae MH, Kim MK, et al. Crystal structure of Rattus norvegicus Visfatin/PBEF/Nampt in complex with an FK866-based inhibitor. Mol Cells. 2009;27:667-671.
39. Garten A, Petzold S, Korner A, et al. Nampt: linking NAD biology, metabolism and cancer. Trends Endocrinol Metab. 2009;20:130-138.
40. Revollo JR, Grimm AA, Imai S. The NAD biosynthesis pathway mediated by nicotinamide phosphoribosyltransferase regulates Sir2 activity in mammalian cells. J Biol Chem. 2004;279:50754-50763. (Pubitemid 40017813)
41. van der Veer E, Ho C, O'Neil C, et al. Extension of human cell lifespan by nicotinamide phosphoribosyltransferase. J Biol Chem. 2007;282:10841-10845. (Pubitemid 47100731)
42. Imai S, Guarente L. Ten years of NAD-dependent SIR2 family deacetylases: implications for metabolic diseases. Trends Pharmacol Sci. 2010;31:212-220.
43. Siddiqui S, Brown M, Singleton P, et al. IFITM3 and MmMLCK are required in extracellular PBEF mediated activation of NFkappaB pathway in human lung microvessel endothelium. Am J Respir Crit Care Med 2010;181:A3612.
44. Liu P, Li H, Cepeda J, et al. Regulation of inflammatory cytokine expression in pulmonary epithelial cells by pre-B-cell colony-enhancing factor via a nonenzymatic and AP-1-dependent mechanism. J Biol Chem. 2009;284:27344-27351.
45. Wang P, Xu TY, Guan YF, et al. Perivascular adipose tissue-derived visfatin is a vascular smooth muscle cell growth factor: role of nicotinamide mononucleotide. Cardiovasc Res. 2009;81:370-380.
46. van der Veer E, Nong Z, O'Neil C, et al. Pre-B-cell colony-enhancing factor regulates NAD+-dependent protein deacetylase activity and promotes vascular smooth muscle cell maturation. Circ Res. 2005;97:25-34. (Pubitemid 40982319)
47. Borradaile NM, Pickering JG. Nicotinamide phosphoribosyltransferase imparts human endothelial cells with extended replicative lifespan and enhanced angiogenic capacity in a high glucose environment. Aging Cell. 2009;8:100-112.
48. Cheng KH, Chu CS, Lee KT, et al. Adipocytokines and proinflammatory mediators from abdominal and epicardial adipose tissue in patients with coronary artery disease. Int J Obes (Lond). 2008;32:268-274.
49. Malavazos AE, Ermetici F, Cereda E, et al. Epicardial fat thickness: relationship with plasma visfatin and plasminogen activator inhibitor-1 levels in visceral obesity. Nutr Metab Cardiovasc Dis. 2008;18:523-530.
50. Choi KM, Lee JS, Kim EJ, et al. Implication of lipocalin-2 and visfatin levels in patients with coronary heart disease. Eur J Endocrinol. 2008;158:203-207. (Pubitemid 351298537)
51. Mukherjee S, Lekli I, Gurusamy N, et al. Expression of the longevity proteins by both red and white wines and their cardioprotective components, resveratrol, tyrosol, and hydroxytyrosol. Free Radic Biol Med. 2009;46:573-578.
52. Lim SY, Davidson SM, Paramanathan AJ, et al. The novel adipocytokine visfatin exerts direct cardioprotective effects. J Cell Mol Med. 2008;12:1395-1403.
53. Hsu CP, Oka S, Shao D, et al. Nicotinamide phosphoribosyltransferase regulates cell survival through NAD+ synthesis in cardiac myocytes. Circ Res. 2009;105:481-491.
54. Nadtochiy SM, Redman E, Rahman I, et al. Lysine deacetylation in ischaemic preconditioning: the role of SIRT1. Cardiovasc Res. 2010; doi: 10.1093/cvr/cvq1287.
55. Hsu CP, Hariharan N, Alcendor RR, et al. Nicotinamide phosphoribosyltransferase regulates cell survival through autophagy in cardiomyocytes. Autophagy. 2009;5:1229-1231.
56. Nowell MA, Richards PJ, Fielding CA, et al. Regulation of pre-B cell colony-enhancing factor by STAT-3-dependent interleukin-6 transsignaling: implications in the pathogenesis of rheumatoid arthritis. Arthritis Rheum. 2006;54:2084-2095. (Pubitemid 44051064)
57. McGlothlin JR, Gao L, Lavoie T, et al. Molecular cloning and characterization of canine pre-B-cell colony-enhancing factor. Biochem Genet. 2005;43:127-141. (Pubitemid 40543710)
58. Kim SR, Bae SK, Choi KS, et al. Visfatin promotes angiogenesis by activation of extracellular signal-regulated kinase 1/2. Biochem Biophys Res Commun. 2007;357:150-156.
59. Adya R, Tan BK, Punn A, et al. Visfatin induces human endothelial VEGF and MMP-2/9 production via MAPK and PI3K/Akt signalling pathways: novel insights into visfatin-induced angiogenesis. Cardiovasc Res. 2008;78:356-365. (Pubitemid 351556097)
60. Adya R, Tan BK, Chen J, et al. Pre-B cell colony enhancing factor (PBEF)/visfatin induces secretion of MCP-1 in human endothelial cells: role in visfatin-induced angiogenesis. Atherosclerosis. 2009;205:113-119.
61. Lovren F, Pan Y, Shukla PC, et al. Visfatin activates eNOS via Akt and MAP kinases and improves endothelial cell function and angiogenesis in vitro and in vivo: translational implications for atherosclerosis. Am J Physiol Endocrinol Metab. 2009;296:E1440-E1449.
62. Borradaile NM, Pickering JG. Polyploidy impairs human aortic endothelial cell function and is prevented by nicotinamide phosphoribosyltransferase. Am J Physiol Cell Physiol. 2010;298:C66-C74.
63. Bae YH, Park HJ, Kim SR, et al. Notch1 mediates visfatin-induced FGF-2 up-regulation and endothelial angiogenesis. Cardiovasc Res. 2010;doi: 10.1093/cvr/cvq1276.
64. Adya R, Tan BK, Chen J, et al. Nuclear factor-kappaB induction by visfatin in human vascular endothelial cells: its role in MMP-2/9 production and activation. Diabetes Care. 2008;31:758-760.
65. Iwen KA, Senyaman O, Schwartz A, et al. Melanocortin crosstalk with adipose functions: ACTH directly induces insulin resistance, promotes a pro-inflammatory adipokine profile and stimulates UCP-1 in adipocytes. J Endocrinol. 2008;196:465-472. (Pubitemid 351425502)
66. Kim SR, Bae YH, Bae SK, et al. Visfatin enhances ICAM-1 and VCAM-1 expression through ROS-dependent NF-kappaB activation in endothelial cells. Biochim Biophys Acta. 2008;1783:886-895.
67. Liu SW, Qiao SB, Yuan JS, et al. Visfatin stimulates production of monocyte chemotactic protein-1 and interleukin-6 in human vein umbilical endothelial cells. Horm Metab Res. 2009;41:281-286.
68. Xia M, Zhang C, Boini KM, et al. Membrane raft-lysosome redox signaling platforms in coronary endothelial dysfunction induced by adipokine visfatin. Cardiovasc Res. 2010;doi: 10.1093/cvr/cvq1286.
69. Takebayashi K, Suetsugu M, Wakabayashi S, et al. Association between plasma visfatin and vascular endothelial function in patients with type 2 diabetes mellitus. Metabolism. 2007;56:451-458. (Pubitemid 46427838)
70. Malyszko J, Malyszko JS, Pawlak K, et al. Visfatin and apelin, new adipocytokines, and their relation to endothelial function in patients with chronic renal failure. Adv Med Sci. 2008;53:32-36.
71. Korner A, Garten A, Bluher M, et al. Molecular characteristics of serum visfatin and differential detection by immunoassays. J Clin Endocrinol Metab. 2007;92:4783-4791. (Pubitemid 350223461)
72. Nusken KD, Petrasch M, Rauh M, et al. Active visfatin is elevated in serum of maintenance haemodialysis patients and correlates inversely with circulating HDL cholesterol. Nephrol Dial Transplant. 2009;24:2832-2838.
73. Yilmaz MI, Saglam M, Carrero JJ, et al. Normalization of endothelial dysfunction following renal transplantation is accompanied by a reduction of circulating visfatin/NAMPT. A novel marker of endothelial damage? Clin Transplant. 2009;23:241-248.
74. Yilmaz MI, Saglam M, Qureshi AR, et al. Endothelial dysfunction in type-2 diabetics with early diabetic nephropathy is associated with low circulating adiponectin. Nephrol Dial Transplant. 2008;23:1621-1627. (Pubitemid 351767738)
75. Carrero JJ, Witasp A, Stenvinkel P, et al. Visfatin is increased in chronic kidney disease patients with poor appetite and correlates negatively with fasting serum amino acids and triglyceride levels. Nephrol Dial Transplant. 2010;25:901-906.
76. Song HK, Lee MH, Kim BK, et al. Visfatin: a new player in mesangial cell physiology and diabetic nephropathy. Am J Physiol Renal Physiol. 2008;295:F1485-F1494.
77. Owens GK, Kumar MS, Wamhoff BR. Molecular regulation of vascular smooth muscle cell differentiation in development and disease. Physiol Rev. 2004;84:767-801. (Pubitemid 38823766)
78. Ho C, van der Veer E, Akawi O, et al. SIRT1 markedly extends replicative lifespan if the NAD+ salvage pathway is enhanced. FEBS Lett. 2009;583:3081-3085.
79. Drevs J, Loser R, Rattel B, et al. Antiangiogenic potency of FK866/K22.175, a new inhibitor of intracellular NAD biosynthesis, in murine renal cell carcinoma. Anticancer Res. 2003;23:4853-4858. (Pubitemid 38173905)
80. Hasmann M, Schemainda I. FK866, a highly specific noncompetitive inhibitor of nicotinamide phosphoribosyltransferase, represents a novel mechanism for induction of tumor cell apoptosis. Cancer Res. 2003;63:7436-7442. (Pubitemid 37413486)
81. Romacho T, Azcutia V, Vazquez-Bella M, et al. Extracellular PBEF/NAMPT/visfatin activates pro-inflammatory signalling in human vascular smooth muscle cells through nicotinamide phosphoribosyltransferase activity. Diabetologia. 2009;52:2455-2463.
82. Hansson GK. Inflammation, atherosclerosis, and coronary artery disease. N Engl J Med. 2005;352:1685-1695.
83. Lohn M, Dubrovska G, Lauterbach B, et al. Periadventitial fat releases a vascular relaxing factor. FASEB J. 2002;16:1057-1063. (Pubitemid 34753512)
84. Barandier C, Montani JP, Yang Z. Mature adipocytes and perivascular adipose tissue stimulate vascular smooth muscle cell proliferation: effects of aging and obesity. Am J Physiol Heart Circ Physiol. 2005;289:H1807-H1813. (Pubitemid 41507326)
85. Feletou M, Tang EH, Vanhoutte PM. Nitric oxide the gatekeeper of endothelial vasomotor control. Front Biosci. 2008;13:4198-4217. (Pubitemid 351611598)
86. Busse R, Edwards G, Feletou M, et al. EDHF: bringing the concepts together. Trends Pharmacol Sci. 2002;23:374-380.
87. Rajsheker S, Manka D, Blomkalns AL, et al. Crosstalk between perivascular adipose tissue and blood vessels. Curr Opin Pharmacol. 2010;10:191-196.
88. Gao YJ. Dual modulation of vascular function by perivascular adipose tissue and its potential correlation with adiposity/lipoatrophy-related vascular dysfunction. Curr Pharm Des. 2007;13:2185-2192.
89. Yamawaki H, Hara N, Okada M, et al. Visfatin causes endothelium-dependent relaxation in isolated blood vessels. Biochem Biophys Res Commun. 2009;383:503-508.
90. Rahmouni K, Correia ML, Haynes WG, et al. Obesity-associated hypertension: new insights into mechanisms. Hypertension. 2005;45:9-14. (Pubitemid 40066405)
91. Imai S. Nicotinamide phosphoribosyltransferase (Nampt): a link between NAD biology, metabolism, and diseases. Curr Pharm Des. 2009;15:20-28.
92. Wang P, Du H, Zhang RY, et al. Circulating and local visfatin/Nampt/PBEF levels in spontaneously hypertensive rats, stroke-prone spontaneously hypertensive rats and Wistar-Kyoto rats. J Physiol Sci. 2010;60:317-324.
93. Wang P, Bai C, Xu QY, et al. Visfatin is associated with lipid metabolic abnormalities in Lyon hypertensive rats. Clin Exp Pharmacol Physiol. 2010;37:894-899.
94. Gilibert S, Bataillard A, Nussberger J, et al. Implication of chromosome 13 on hypertension and associated disorders in Lyon hypertensive rats. J Hypertens. 2009;27:1186-1193.
95. Dogru T, Sonmez A, Tasci I, et al. Plasma visfatin levels in young male patients with uncomplicated and newly diagnosed hypertension. J Hum Hypertens. 2007;21:173-175.
96. Guzik TJ, Mangalat D, Korbut R. Adipocytokines-novel link between inflammation and vascular function? J Physiol Pharmacol. 2006;57:505-528. (Pubitemid 46096102)
97. Beltowski J. Apelin and visfatin: unique "beneficial" adipokines upregulated in obesity? Med Sci Monit. 2006;12:RA112-RA119. (Pubitemid 43854434)
98. Curat CA, Wegner V, Sengenes C, et al. Macrophages in human visceral adipose tissue: increased accumulation in obesity and a source of resistin and visfatin. Diabetologia. 2006;49:744-747. (Pubitemid 43357549)
99. Dahl TB, Yndestad A, Skjelland M, et al. Increased expression of visfatin in macrophages of human unstable carotid and coronary atherosclerosis: possible role in inflammation and plaque destabilization. Circulation. 2007;115:972-980. (Pubitemid 46328290)
100. Zhong M, Tan HW, Gong HP, et al. Increased serum visfatin in patients with metabolic syndrome and carotid atherosclerosis. Clin Endocrinol (Oxf). 2008;69:878-884.
101. Kadoglou NP, Sailer N, Moumtzouoglou A, et al. Visfatin (nampt) and ghrelin as novel markers of carotid atherosclerosis in patients with type 2 diabetes. Exp Clin Endocrinol Diabetes. 2010;118:75-80.
102. Mu J, Feng B, Ye Z, et al. Visfatin is related to lipid dysregulation, endothelial dysfunction and atherosclerosis in patients with chronic kidney disease. J Nephrol. 2010; Epub ahead of print.
103. Kato A, Odamaki M, Ishida J, et al. Relationship between serum pre-B cell colony-enhancing factor/visfatin and atherosclerotic parameters in chronic hemodialysis patients. Am J Nephrol. 2009;29:31-35.
104. Rho YH, Chung CP, Solus JF, et al. Adipocytokines, insulin resistance, and coronary atherosclerosis in rheumatoid arthritis. Arthritis Rheum. 2010;62:1259-1264.
105. Li Y, Zhang Y, Dorweiler B, et al. Extracellular Nampt promotes macrophage survival via a nonenzymatic interleukin-6/STAT3 signaling mechanism. J Biol Chem. 2008;283:34833-34843.
106. Fu H, Zhu Y, You GY, et al. Detection of visfatin level of plasma in patients with coronary artery diseases. Sichuan Da Xue Xue Bao Yi Xue Ban. 2009;40:322-324.
107. Liu SW, Qiao SB, Yuan JS, et al. Association of plasma visfatin levels with inflammation, atherosclerosis and acute coronary syndromes (ACS) in humans. Clin Endocrinol (Oxf). 2009;71:202-207.
108. Kadoglou NP, Gkontopoulos A, Kapelouzou A, et al. Serum levels of vaspin and visfatin in patients with coronary artery disease-Kozani study. Clin Chim Acta. 2010;doi:10.1016/j.cca.2010.1009.1012.
109. Donnan GA, Fisher M, Macleod M, et al. Stroke. Lancet. 2008;371:1612-1623. (Pubitemid 351626845)
110. He J, Gu D, Wu X, et al. Major causes of death among men and women in China. N Engl J Med. 2005;353:1124-1134. (Pubitemid 41317435)
111. Bazzano LA, Gu D, Whelton MR, et al. Body mass index and risk of stroke among Chinese men and women. Ann Neurol. 2010;67:11-20.
112. Kurth T, Leitzmann MF. Awakening of the sleeping giant: obesity and stroke in China. Ann Neurol. 2010;67:1-2.
113. Arumugam TV, Phillips TM, Cheng A, et al. Age and energy intake interact to modify cell stress pathways and stroke outcome. Ann Neurol. 2010;67:41-52.
114. Yager JY, Thornhill JA. The effect of age on susceptibility to hypoxic-ischemic brain damage. Neurosci Biobehav Rev. 1997;21:167-174. (Pubitemid 27102561)
115. Jickling GC, Xu H, Stamova B, et al. Signatures of cardioembolic and large-vessel ischemic stroke. Ann Neurol. 2010;68:681-692.
116. Guo JM, Liu AJ, Su DF. Genetics of stroke. Acta Pharmacol Sinica. 2010;31:1055-1064.
117. Anderson CD, Biffi A, Rahman R, et al. Common mitochondrial sequence variants in ischemic stroke. Ann Neurol. 2010;doi/10.1002/ana.22108.
118. Vilela P, Goulao A. Ischemic stroke: carotid and vertebral artery disease. Eur Radiol. 2005;15:427-433. (Pubitemid 40347884)
119. Qureshi AI, Feldmann E, Gomez CR, et al. Intracranial atherosclerotic disease: an update. Ann Neurol. 2009;66:730-738.
120. Cline MA, Nandar W, Prall BC, et al. Central visfatin causes orexigenic effects in chicks. Behav Brain Res. 2008;186:293-297. (Pubitemid 350122761)
121. Reddy PS, Umesh S, Thota B, et al. PBEF1/NAmPRTase/Visfatin: a potential malignant astrocytoma/glioblastoma serum marker with prognostic value. Cancer Biol Ther. 2008;7:663-668.
122. Lu LF, Yang SS, Wang CP, et al. Elevated visfatin/pre-B-cell colony-enhancing factor plasma concentration in ischemic stroke. J Stroke Cerebrovasc Dis. 2009;18:354-359.
123. Wang P, Xu TY, Guan YF, et al. Nicotinamide phosphoribosyltransferase protects against ischemic stroke through SIRT1-dependent adenosine monophosphate-activated kinase pathway. Ann Neurol. 2010;doi: 10.1002/ana.22236.
124. Zhang W, Xie Y, Wang T, et al. Neuronal protective role of PBEF in a mouse model of cerebral ischemia. J Cereb Blood Flow Metab. 2010; doi: 10.1038/jcbfm.2010.1071.
125. Zhang W, Liu AJ, Yi-Ming W, et al. Pressor and non-pressor effects of sodium loading on stroke in stroke-prone spontaneously hypertensive rats. Clin Exp Pharmacol Physiol. 2008;35:83-88. (Pubitemid 350197685)
126. Brown J, Onyango D, Ramanjaneya M, et al. Visfatin regulates insulin secretion, insulin receptor signalling and mRNA expression of diabetes related genes in mouse pancreatic beta-cells. J Mol Endocrinol. 2010;44:171-178.
127. Moschen AR, Molnar C, Wolf AM, et al. Effects of weight loss induced by bariatric surgery on hepatic adipocytokine expression. J Hepatol. 2009;51:765-777.
128. Costford SR, Bajpeyi S, Pasarica M, et al. Skeletal Muscle NAMPT is Induced by Exercise in Humans. Am J Physiol Endocrinol Metab. 2010;298:E117-E126.
129. Frydelund-Larsen L, Akerstrom T, Nielsen S, et al. Visfatin mRNA expression in human subcutaneous adipose tissue is regulated by exercise. Am J Physiol Endocrinol Metab. 2007;292:E24-E31. (Pubitemid 46052921)
130. Kralisch S, Klein J, Lossner U, et al. Interleukin-6 is a negative regulator of visfatin gene expression in 3T3-L1 adipocytes. Am J Physiol Endocrinol Metab. 2005;289:E586-E590. (Pubitemid 41356079)
131. Hong SB, Huang Y, Moreno-Vinasco L, et al. Essential role of pre-B-cell colony enhancing factor in ventilator-induced lung injury. Am J Respir Crit Care Med. 2008;178:605-617.
132. Ye SQ, Simon BA, Maloney JP, et al. Pre-B-cell colony-enhancing factor as a potential novel biomarker in acute lung injury. Am J Respir Crit Care Med. 2005;171:361-370. (Pubitemid 40223404)
133. Jia SH, Li Y, Parodo J, et al. Pre-B cell colony-enhancing factor inhibits neutrophil apoptosis in experimental inflammation and clinical sepsis. J Clin Invest. 2004;113:1318-1327. (Pubitemid 39069931)
134. Skokowa J, Lan D, Thakur BK, et al. NAMPT is essential for the G-CSF-induced myeloid differentiation via a NAD(+)-sirtuin-1-dependent pathway. Nat Med. 2009;15:151-158.
135. Van Gool F, Galli M, Gueydan C, et al. Intracellular NAD levels regulate tumor necrosis factor protein synthesis in a sirtuin-dependent manner. Nat Med. 2009;15:206-210.
136. Vrablik TL, Huang L, Lange SE, et al. Nicotinamidase modulation of NAD+ biosynthesis and nicotinamide levels separately affect reproductive development and cell survival in C. elegans. Development. 2009;136:3637-3646.
137. Moschen AR, Geiger S, Gerner R, et al. Pre-B cell colony enhancing factor/NAMPT/visfatin and its role in inflammation-related bone disease. Mutat Res. 2010;690:95-101.
138. Nakajima TE, Yamada Y, Hamano T, et al. Adipocytokines and squamous cell carcinoma of the esophagus. J Cancer Res Clin Oncol. 2010;136:261-266.
139. Nakajima TE, Yamada Y, Hamano T, et al. Adipocytokine levels in gastric cancer patients: resistin and visfatin as biomarkers of gastric cancer. J Gastroenterol. 2009;44:685-690.
140. Patel ST, Mistry T, Brown JE, et al. A novel role for the adipokine visfatin/pre-B cell colony-enhancing factor 1 in prostate carcinogenesis. Peptides. 2009;31:51-57.
141. Wang B, Hasan MK, Alvarado E, et al. NAMPT overexpression in prostate cancer and its contribution to tumor cell survival and stress response. Oncogene. 2010;doi: 10.1038/onc.2010.1468.
142. Dupre SM, Burt DW, Talbot R, et al. Identification of melatonin-regulated genes in the ovine pituitary pars tuberalis, a target site for seasonal hormone control. Endocrinology. 2008;149:5527-5539.
143. Imai S. "Clocks" in the NADWorld: NAD as a metabolic oscillator for the regulation of metabolism and aging. Biochim Biophys Acta. 2010;1804:1584-1590.